Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells;a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform; and research collaboration with AstraZeneca PLC to evaluate novel potential therapeutic cell applications. The company was incorporated in 1998 and is headquartered in London, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.15304347826086956 | N/A |
Market Cap | $46.42M | N/A |
Shares Outstanding | 303.33M | 10.87% |
Employees | 0 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$27.13M | N/A |